Stimulator of Interferon Genes (STING)

Where the papers sit

11 papers from the last 6 months study Stimulator of Interferon Genes (STING) directly · updated from PubMed 12 Oct 2026

• STING Cancer Immunotherapy

  STING activation is being paired with vaccines, radiotherapy, and immune-checkpoint targeting to convert immune-silent tumors into T-cell-responsive disease. Personalized autologous vaccines and dendritic-cell PD-L1 suppression aim to improve antigen presentation, while Mn2+-releasing nanoparticles enhance radio-immunotherapy. TIGIT nanotrapping addresses T-cell exhaustion and innate immune silence, whereas dendritic-cell autophagy and neutrophils emerge as limits to intratumoral treatment. The field is moving toward combination regimens that remodel both myeloid and lymphoid resistance mechanisms.

  5 papers · 45.5%

• Inflammation-Targeted Nanotherapy

  Redox control, immune modulation, and targeted delivery recur across therapies for autoimmune, fibrotic, and malignant disease. Reactive oxygen species scavenging is paired with immunomodulation in autoimmune uveitis, while tumor microenvironment cues activate RNA-boosted photo-STING therapy. In pulmonary fibrosis, inhaled PROTAC nanococktails shift attention toward localized protein degradation. The shared direction is multifunctional nanomedicine, but the disease settings and mechanisms remain distinct.

  3 papers · 27.3%

• STING-Driven Inflammation

  STING inhibition is being developed across autoinflammatory, neuroinflammatory, and infectious disease contexts. Monotropein and the herbal formulation JieZe-1 are linked to reduced cGAS/STING signaling alongside improvement in inflammatory or coinfective outcomes. A molecular glue instead induces aberrant STING oligomerization, showing that noncanonical pathway modulation can suppress autoinflammation without simple pathway blockade. The recurring focus is translating molecular and cellular STING measurements into disease-directed anti-inflammatory therapy.

  3 papers · 27.3%